Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how long-term LEAP-002 data provides critical reassurance around Lenvima’s durability and safety in treating ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the drug discovery research for lecanemab (product name Leqembi®), an antibody indicated for early Alzheimer's ...

The Bioindustry Award, now marking its 9th year, recognizes achievements that have significantly contributed to the development of the bioindustry or are expected to contribute to its future growth.

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. Urece ...

URECE is a new therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. It suppresses uric acid reabsorption and lowers blood uric acid levels by selectively inhibiting the urate ...

Visakhapatnam: Eisai Pharma, a noted human health care pharmaceutical company, announced its plans to establish a new global ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

Eisai Pharma, a noted human health care pharmaceutical company with a global presence, announced its plans to establish a new ...

Japanese authorities are putting Eisai (TYO: 4523) under pressure to reconsider the price of its Alzheimer’s disease therapy ...

Eisai Pharma is set to establish a new Global Capability Center (GCC) in Visakhapatnam, aiming to boost its digital ...